Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Erasmus MC, Rotterdam University, Rotterdam, the Netherlands.
Cancer Res. 2022 Oct 17;82(20):3637-3649. doi: 10.1158/0008-5472.CAN-22-1525.
Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.
免疫检查点阻断疗法已成功应用于多种癌症，特别是那些具有高突变负担并因此表达高丰度新抗原的肿瘤。然而，需要新的方法来提高免疫疗法治疗缺乏高负荷经典遗传衍生新抗原的肿瘤的疗效。最近发现了广泛的非遗传编码和诱导性新表位类别，为增强对免疫疗法的敏感性开辟了新的治疗开发途径。在这篇综述中，我们讨论了新抗原发现的最新工作，重点介绍了新型非典型新表位。
